Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American journal of ophthalmology-glaucoma

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajo.2010.11.019PMID 21334595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high‐resolution, spectral‐domain optical coherence tomography

  2010cited by this paper
• Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2

  2010cited by this paper
• Structure-Function Correlation of the Human Central Retina

  2010cited by this paper
• Intravitreal bevacizumab therapy for idiopathic macular telangiectasia

  2010cited by this paper
• Intravitreous ranibizumab as treatment for macular telangiectasia type 2.

  2010cited by this paper
• The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study.

  2010cited by this paper
• [Idiopathic macular telangiectasia - follow-up with and without laser photocoagulation].

  2010cited by this paper
• Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

  2010cited by this paper
• Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments.

  2009cited by this paper
• Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2.

  2009cited by this paper
• The article by Kovach and Rosenfeld.

  2009cited by this paper
• BEVACIZUMAB (AVASTIN) THERAPY FOR IDIOPATHIC MACULAR TELANGIECTASIA TYPE II

  2009cited by this paper
• Subconjunctival Loa loa: first case report from Norway

  2009cited by this paper
• Comment on macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia.

  2009cited by this paper
• Familial asymptomatic macular telangiectasia type 2.

  2009cited by this paper
• Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia

  2009cited by this paper
• Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia

  2009cited by this paper
• Metamorphopsia in patients with macular telangiectasia type 2

  2009cited by this paper
• Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2.

  2009cited by this paper
• Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia.

  2008cited by this paper
• ABNORMAL MACULAR PIGMENT DISTRIBUTION IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA

  2008cited by this paper
• Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia

  2008cited by this paper
• Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors

  2008cited by this paper
• Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia.

  2008cited by this paper
• Bevacizumab in the treatment of idiopathic macular telangiectasia

  2008cited by this paper
• The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project.

  2008cited by this paper
• Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia.

  2008cited by this paper
• A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging

  2008cited by this paper
• Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane

  2007cited by this paper
• Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.

  2007cited by this paper
• OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN NONPROLIFERATIVE GROUP 2A IDIOPATHIC JUXTAFOVEAL RETINAL TELANGIECTASIS

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

  2007cited by this paper
• Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

  2007cited by this paper
• Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.

  2007cited by this paper
• Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis

  2007cited by this paper
• Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia.

  2007cited by this paper
• Idiopathic Macular Telangiectasia

  2007cited by this paper
• Optical Coherence Tomography Evaluation of Macular Edema after Intravitreal Triamcinolone Acetonide in Patients with Parafoveal Telangiectasis

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography.

  2006cited by this paper
• Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis.

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE

  2005cited by this paper
• LONG-TERM JUXTAFOVEAL RETINAL TELANGIECTASIA

  2005cited by this paper
• [Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

  2005cited by this paper
• Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization.

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation.

  1999cited by this paper
• Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.

  1999cited by this paper
• Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis.

  1997cited by this paper
• Idiopathic juxtafoveolar retinal telangiectasis

  1993cited by this paper
• Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study.

  1993cited by this paper

• Intravitreal Faricimab for the Management of Bilateral Macular Neovascularization Secondary to Macular Telangiectasia Type 2

  2025cites this paper
• Clinical histopathology and pathogenesis of macular telangiectasia type 2.

  2025cites this paper
• The spectrum of microcystic macular edema: Pathogenetic insights, clinical entities and functional prognosis.

  2025cites this paper
• Microcystic Macular Edema: Clinical Significance and Pathogenetic Mechanisms

  2025cites this paper
• A case of macular telangiectasia type 2 with bilateral macular holes: Imaging features and surgical management

  2025cites this paper
• Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2

  2024cites this paper
• Sight threatening diabetic retinopathy in patients with macular telangiectasia type 2

  2024cites this paper
• PATHOGENESIS, PROGNOSIS, AND SURGICAL OUTCOMES OF FULL-THICKNESS MACULAR HOLES IN MACULAR TELANGIECTASIA TYPE 2

  2024cites this paper
• Retinal pigment epithelial cells reduce vascular leak and proliferation in retinal neovessels

  2024cites this paper
• Non-vasogenic cystoid maculopathies.

  2022cites this paper
• Optical Coherence Tomography Angiography for Macular Telangiectasia Type 2

  2022cites this paper
• Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization

  2022cites this paper
• Macular Telangiectasia Type 2: A Comprehensive Review

  2022cites this paper
• Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

  2021cites this paper
• Morphological characteristics preceding exudative neovascularisation secondary to macular telangiectasia type 2

  2021cites this paper
• FUNCTIONAL AND STRUCTURAL EFFECTS OF NONDAMAGING RETINAL LASER THERAPY FOR MACULAR TELANGIECTASIA TYPE 2: A Randomized Sham-Controlled Clinical Trial.

  2020cites this paper
• Retinal microglia are critical for subretinal neovascular formation.

  2020cites this paper
• Idiopathic Macular Telangiectasia

  2020cites this paper
• Subretinal Neovascularization Associated with Idiopathic Juxtafoveal Telangiectasia

  2020cites this paper
• The Diagnosis and Management of Macular Telangiectasia.

  2019cites this paper
• Surgical Outcomes of Macular Telangiectasia Type 2 Associated with Macular Hole

  2019cites this paper
• Ophthalmic Diagnostic Imaging: Retina

  2019cites this paper
• Multicolour imaging signatures to diagnose concurrent macular telangiectasia type 2 and macular branch retinal vein occlusion

  2019cites this paper
• Non-proliferative type II macular telangiectasia variant with subfoveal detachment: role of anti-VEGF therapy

  2019cites this paper
• Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia

  2019cites this paper
• Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm

  2019cites this paper
• Management of Idiopathic Macular Telangiectasia Type 2

  2019cites this paper
• Long-Term Follow-Up of an Atypical Case of Idiopathic Macular Telangiectasia.

  2018cites this paper
• Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm

  2018cites this paper
• OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study

  2017cites this paper
• Diagnosis and management of a patient with idiopathic macular telangiectasia type 2

  2017cites this paper
• Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia

  2017cites this paper
• Intravitreal Ranibizumab Treatment for Non-Proliferative Idiopathic Macular Telangiectasia

  2017cites this paper
• Treatment Modalities for Idiopathic Macular Telangiectasia: An Evidence-Based Systematic Review of the Literature

  2017influential citation
• EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE

  2017cites this paper
• [Inefficacy of aflibercept in the treatment of idiopathic macular telangiectasia type 2 without neovascularization].

  2017cites this paper
• CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6–The MacTel Research Group

  2017cites this paper
• Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia

  2017cites this paper
• Inefficacité de l’aflibercept dans le traitement des télangiectasies maculaires idiopathiques de type 2 sans néovascularisation

  2017cites this paper
• VEGF-Inhibition in Macular Telangiectasia Type 2

  2016cites this paper
• Macular telangiectasia type 2 accompanied by solitary retinal astrocytic hamartoma (case report)

  2016cites this paper
• Treatment for Macular Telangiectasia Type 2.

  2016cites this paper
• LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2

  2016cites this paper
• Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

  2016cites this paper
• Treatment of Macular Telangiectasia Type 2 With Carotenoid Supplements Containing Meso-Zeaxanthin: A Pilot Study.

  2016cites this paper
• Salient features and management options of macular telangiectasia type 2: a review and update

  2016cites this paper
• Maladie de Coats et télangiectasies

  2016cites this paper
• Progression of Vision Loss in Macular Telangiectasia Type 2.

  2015cites this paper
• A New CRB1 Rat Mutation Links Müller Glial Cells to Retinal Telangiectasia

  2015cites this paper
• When is macular edema not macular edema? An update on macular telangiectasia type 2☆

  2015cites this paper
• Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel): Results from a phase I safety trial

  2015cites this paper
• SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF NEOVASCULAR MACULAR TELANGIECTASIA TYPE 2

  2015cites this paper
• Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

  2015cites this paper
• POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2

  2015cites this paper
• Therapeutische Ansätze bei makulären Teleangiektasien Typ 2

  2014cites this paper
• DECREASED MACULAR THICKNESS IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2 WITH ORAL CARBONIC ANHYDRASE INHIBITORS

  2014cites this paper
• RANIBIZUMAB FOR MACULAR TELANGIECTASIA TYPE 2 IN THE ABSENCE OF SUBRETINAL NEOVASCULARIZATION

  2014cites this paper
• Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2).

  2013influential citation
• Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia

  2013cites this paper
• Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

  2013cites this paper
• Long-term course in type 2 idiopathic macular telangiectasia

  2013cites this paper
• Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia

  2013cites this paper
• Macular telangiectasia type 2.

  2013cites this paper
• Chapter 55 – Macular Telangiectasia

  2013cites this paper
• Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia

  2013cites this paper
• Insight into intraretinal crystalline deposits in type 2 macular telangiectasia

  2012cites this paper
• EFFICACY OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN SUBRETINAL NEOVASCULARIZATION SECONDARY TO MACULAR TELANGIECTASIA TYPE 2

  2012cites this paper
• TREATMENT OF NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 WITH INTRAVITREAL RANIBIZUMAB: Results of a Phase II Clinical Trial

  2012cites this paper
• Neue Therapieoptionen bei retinalen Erkrankungen: Was bringt die Zukunft?

  2011cites this paper
• Retinal crystals in type 2 idiopathic macular telangiectasia.

  2010cites this paper